Navigation Links
Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m
Date:1/28/2009

LONDON, January 28 /PRNewswire/ -- Immune Targeting Systems (ITS) Limited, a company developing synthetic vaccines for mutating viruses, today announced it has received GBP2.4m of investment as the second tranche of its series-A funding round. ITS's investors HealthCap, the London Technology Fund, Novartis Venture Fund & Truffle Capital provided additional funding to enable a seamless transition into the clinic for the company's universal flu vaccine program which has now entered the GMP pre-clinical phase.

Simultaneously ITS has moved to strengthen its board and management team with the appointment of Brenda Reynolds, a co-founder of PowderMed (acquired by Pfizer in 2006), as company director. Another seasoned vaccine industry professional, Jill Makin, former VP of R&D for Emergent Biosolutions and Microscience, also joins in a consultancy capacity and is responsible for the GMP vaccine manufacture and its release to the clinic.

ITS CEO Carlton Brown commented: "Brenda and Jill are valuable additions to the team and will help drive both our clinical and commercial programs forward. The second tranche of investment brings our total funding to more than GBP5m, including a GBP0.5m development grant from the London Development Agency. We are aiming to raise series-B investment in 2009 to fund our universal influenza vaccine clinical program to proof-of-concept and bring other prioritized candidates through the pipeline. We expect to commence the clinical program by the end of 2009. Despite the current economic climate, our research tells us that the market remains strong for both a successful universal influenza vaccine and therapeutic T-cell vaccine platform."

    Corporate Inquiries
    Carlton Brown; Chief Executive Officer
    Tel +44-7970-944-454, +44-20-7691-4908
    Email: carlton.brown@its-innovation.co.uk


'/>"/>
SOURCE Immune Targeting Systems (ITS) Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Innovative Beverage Products Launches New Product Designed to Enhance the Bodys Immune Defense
2. Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimers Disease Drug Development
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
5. IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant
6. MedImmune Announces Zook as President
7. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
8. Visualizing asthma-causing immune cells at work
9. Protein-printing technique gives snapshots of immune system defense
10. Peptimmune Presentations at Upcoming Events
11. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... , ... July 18, 2017 , ... ... the United States Patent and Trademark Office for its Patent Applications 14/858,857 and ... Office’s allowances of these patent applications further expand the protection of G-CON’s R&D ...
(Date:7/18/2017)... ... July 18, 2017 , ... Recently recognized ... https://dataformsoftware.com ) announces the migration of its flagship cloud-based product Planet Life Cycle ... team-centric, enterprise work management system that merges strategic and financial planning with execution. ...
(Date:7/17/2017)... ... July 17, 2017 , ... Bioclinica®, ... company AB Cube has joined its eHealth App xChange ™, an ... across life sciences and healthcare. Under the partnership, AB Cube’s comprehensive, cloud-based ...
(Date:7/17/2017)... PHILADELPHIA (PRWEB) , ... July 17, 2017 , ... ... attorney Weihong Hsing, Ph.D. , recently participated in the BiG (Biomedical Innovation ... Shanghai, was dominated by discussions of CAR-T (chimeric antigen receptor T-cell) therapy, a ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):